UNSPSC 51162727: Guaifenesin

This classification denotes an expectorant with the molecular formula C10H14O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 495W7451VQ, chemically known as 1,2,3-propanetriol, ether with 2-methoxyphenol but more generally known as guaifenesin, which bears US NIH Compound Identifier 3516. European Medicines Agency schedules Guaifenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07973MIG.

UNSPSC 51162727 Guaifenesin, a Commodity code, covers pharmaceutical products sourced through state and local procurement channels, though the recent opportunities tagged under this code show a broader mix of pharmaceutical and OTC procurement rather than guaifenesin-specific buying. State and local issuing bodies soliciting under related pharmaceutical codes range from county health departments to multistate cooperative purchasing alliances. Seminole County, Florida, for example, issued an IFB in June 2026 for naloxone and drug deactivation systems, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. These opportunities reflect procurement focused on community health initiatives, emergency response supplies, and broad pharmaceutical distribution networks rather than single-ingredient pharmaceutical components.

The most recent activity appears concentrated in the Upper Midwest and Southeast. MMCAP's January 2026 RFP covers Minnesota and Oregon with an effective contract date of July 1, 2026, and Seminole County's June 2026 IFB (IFB60459723LAS) targets naloxone and deactivation systems with a response deadline of July 26, 2023. Vendors responding to MMCAP must work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), maintain cGMP and DSCSA compliance, carry commercial general liability insurance of $5 million per occurrence, and accept a 3 percent administrative fee on all purchases. Seminole County requires E-Verify compliance, drug-free workplace certification, quarterly deliveries, and a two-year initial term with optional one-year renewal. Neither solicitation explicitly designates set-asides for disadvantaged enterprises, though both require standard federal and state compliance certifications.